Espinel-Ingroff A, Shadomy S
Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0504.
Eur J Clin Microbiol Infect Dis. 1989 Apr;8(4):352-61. doi: 10.1007/BF01963469.
The evaluation of any antifungal agent involves the determination of its in vitro and in vivo activity against pathogenic and/or opportunistic fungi. The in vitro evaluation is followed by an in vivo evaluation in animal models, and clinical trials in humans. From the first report of the efficacy of the iodides for the treatment of sporotrichosis (1903) until the introduction of the imidazoles (azoles, 1960s), the number of antifungal agents available was very limited, including griseofulvin (1939), nystatin (1950), amphotericin B (1956), and flucytosine (1964). This paper briefly reviews the status of the antifungal agents currently used, and gives a more in depth evaluation of progress during recent years in the search for new antifungal drugs. Efforts to improve the efficacy of the current antifungal agents are also reviewed.
对任何抗真菌药物的评估都涉及确定其对致病性和/或机会性真菌的体外和体内活性。体外评估之后是在动物模型中的体内评估以及在人类中的临床试验。从关于碘化物治疗孢子丝菌病疗效的首次报告(1903年)到咪唑类药物(唑类,20世纪60年代)问世,可用的抗真菌药物数量非常有限,包括灰黄霉素(1939年)、制霉菌素(1950年)、两性霉素B(1956年)和氟胞嘧啶(1964年)。本文简要回顾了目前使用的抗真菌药物的状况,并对近年来寻找新型抗真菌药物的进展进行了更深入的评估。同时也回顾了提高现有抗真菌药物疗效的努力。